ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 16 Oct 2017
Last Updated on 31 Aug 2022
A- A+
Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Guidance is outdated and has been withdrawn on 31 August 2022.
Insulin Glargine Biosimilar (Withdrawn 31 Aug 22)